Vertex Pharmaceuticals (VRTX) Osake Kurssi
Vertex Pharmaceuticals Kurssi
Viimeisten 19 vuoden aikana Vertex Pharmaceuticalsn liikevaihto kasvoi 23,6 % vuodessa ja ylsi 12,07 Mrd. USD:een. Osakekohtainen tulos on kasvanut 40,3 % vuodessa viimeisten 14 vuoden aikana. Vertex Pharmaceuticalsn nettomarginaali 32,7 % on noussut verrattuna 30,9 %:iin muutama vuosi sitten. Vertex Pharmaceuticalsn 12 kuukauden konsensustavoitehinta on 580,00 USD, noin yli kurssia 14,7 %. 36 analyytikosta 29 suosittaa ostoa — kokonaiskonsensus on Osta.
Vertex Pharmaceuticals osakekurssi
Vertex Pharmaceuticals liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Vertex Pharmaceuticals -osakkeesta
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.
Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.
Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.
Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.
Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.
Analyytikot asettavat tällä hetkellä Vertex Pharmaceuticals-osakkeelle keskimääräisen tavoitehinnan 553,08 USD (mediaani: 580,00 USD), mikä merkitsee +9,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 36 analyytikkoarvioon.
36 analyytikkoa arvioi tällä hetkellä Vertex Pharmaceuticals-osaketta: 29 suosittaa ostoa, 6 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Vertex Pharmaceuticals-yhtiöltä 13,23 Mrd. USD liikevaihtoa ja 18,50 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Vertex Pharmaceuticals-osake noteerataan hintaan 451,51 EUR (505,64 USD).
Vertex Pharmaceuticals-osake (VRTX) on listattuna 11 pörssissä, muun muassa: NASDAQ (VRTX), London (0QZU.L), SIX (Zürich) (VRTX.SW), XETRA (VX1.DE), Frankfurt (VX1.F), München (VX1.MU), Düsseldorf (VX1.DU), Hamburg (VX1.HM).
Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.
odotettu liikevaihto Vertex Pharmaceuticals on 13,23 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Vertex Pharmaceuticals on 4,74 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Vertex Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä 27,34. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Vertex Pharmaceuticals-osakkeen arvostusta.
Vertex Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 9,78. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Vertex Pharmaceuticals-osakkeen arvostuskennuslukuna.
Vertex Pharmaceuticals:n Eulpool-laatuscore on 5/10.
Vertex Pharmaceuticals:n ISIN on US92532F1003. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Vertex Pharmaceuticals:n WKN on 882807. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Vertex Pharmaceuticals:n ticker on VRTX. Tämä pörssinoteeraus käytetään Vertex Pharmaceuticals-osakkeiden kauppaan pörssissä.
Vertex Pharmaceuticals osake
Vertex Pharmaceuticals vertaisryhmä
Vertex Pharmaceuticals Ticker
Vertex Pharmaceuticals FIGI
Kaikki tunnusluvut ja syvällinen analyysi Vertex Pharmaceuticals:sta
Meidän osakeanalyysimme Vertex Pharmaceuticals-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Vertex Pharmaceuticals:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: